The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated×3•Originally published 15 April 2026•Updated 17 April 2026•

1 min read

Hollywood Professionals Oppose $110 Billion Paramount-Warner Bros Merger

Key Facts

1More than 1,000 actors, directors, and screenwriters signed a letter opposing the $110 billion takeover deal.

about 2 months ago

Version History

Version 3about 2 months ago

What changed: Updated the story to include Skydance nearing $24 billion in financing from Middle East sovereign wealth funds to back the merger bid.

Version 2about 2 months ago

What changed: Updated the story to include Skydance CEO David Ellison's commitment to release 30 films annually to garner support for the acquisition.

Version 1about 2 months ago

What changed: The story was updated to include the financial market's shift toward a 'hostile rewrite' of the deal terms, reflecting investment skepticism beyond the initial opposition from industry talent.

The proposed $110 billion merger between Paramount Global and Warner Bros. Discovery has reached a critical financial milestone as Skydance nears securing $24 billion in backing from Middle East sovereign wealth funds. This massive capital injection is intended to solidify David Ellison’s bid and address the complex financing requirements of the acquisition. Alongside this financial push, Ellison has maintained his strategic promise to theater owners to release at least 30 films annually to counter industry skepticism. Despite the new funding, the deal continues to face stiff resistance from over 1,000 Hollywood professionals concerned about monopolistic impacts and job losses. Market participants are now closely evaluating how this Middle Eastern sovereign support will influence regulatory approvals and the stock performance of PARA and WBD. The infusion of capital marks a tactical shift from operational promises to concrete financial readiness.